Human STEAP3 mutations with no phenotypic red cell changes.

To the editor: During recent years, variants in iron metabolism genes have been identified as molecular etiologic factors of hereditary microcytic anemias, such as iron-refractory iron deficiency anemia caused by TMPRSS6 mutations, hypotransferrinemia resulting from TF mutations, congenital

[1]  H. Hatabu,et al.  Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in Waldenström Macroglobulinemia as a Paradigm. , 2015, The oncologist.

[2]  R. Pazdur,et al.  FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia , 2015, Clinical Cancer Research.

[3]  Michael L. Wang,et al.  Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. , 2015, Blood.

[4]  M. Dlakić,et al.  Characterization of a Single b-type Heme, FAD, and Metal Binding Sites in the Transmembrane Domain of Six-transmembrane Epithelial Antigen of the Prostate (STEAP) Family Proteins* , 2015, The Journal of Biological Chemistry.

[5]  S. Schuster,et al.  Management of chronic lymphocytic leukemia (CLL) in the era of B‐cell receptor signal transduction inhibitors , 2015, American journal of hematology.

[6]  G. Kempermann.  Faculty Opinions recommendation of Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. , 2015 .

[7]  R. Matthay,et al.  Drug-induced pulmonary disease. , 2015, Disease-a-month : DM.

[8]  Jeffrey A Jones,et al.  Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. , 2015, Blood.

[9]  R. Advani,et al.  Ibrutinib in previously treated Waldenström's macroglobulinemia. , 2015, The New England journal of medicine.

[10]  G. Debnath,et al.  Abnormal erythroid maturation leads to microcytic anemia in the TSAP6/Steap3 null mouse model , 2015, American journal of hematology.

[11]  D. Weatherall,et al.  The α-thalassemias. , 2014, The New England journal of medicine.

[12]  M. Fleming,et al.  Sideroblastic anemia: diagnosis and management. , 2014, Hematology/oncology clinics of North America.

[13]  J. Byrd,et al.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. , 2014, The New England journal of medicine.

[14]  D. Swinkels,et al.  Practice guidelines for the diagnosis and management of microcytic anemias due to genetic disorders of iron metabolism or heme synthesis. , 2014, Blood.

[15]  J. Friedberg,et al.  Phase 2 trial of GS-9973, a selective syk inhibitor, and idelalisib (idela) in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). , 2014 .

[16]  A. Zelenetz,et al.  Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. , 2014, The New England journal of medicine.

[17]  J. Johnston,et al.  Btk Regulates Macrophage Polarization in Response to Lipopolysaccharide , 2014, PloS one.

[18]  Michael L. Wang,et al.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. , 2013, The New England journal of medicine.

[19]  Juthamas Sukbuntherng,et al.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.

[20]  Yuanyuan Shen,et al.  Metalloreductase Steap3 coordinates the regulation of iron homeostasis and inflammatory responses , 2012, Haematologica.

[21]  I. Matsumoto,et al.  The STEAP protein family: Versatile oxidoreductases and targets for cancer immunotherapy with overlapping and distinct cellular functions , 2012, Biology of the cell.

[22]  A. Palazzo,et al.  Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials , 2012, Acta oncologica.

[23]  H. Heimpel,et al.  A novel type of congenital hypochromic anemia associated with a nonsense mutation in the STEAP3/TSAP6 gene. , 2011, Blood.

[24]  L. Holm,et al.  The Pfam protein families database , 2011, Nucleic Acids Res..

[25]  Maxine Sun,et al.  Molecular epidemiological survey of haemoglobinopathies in the Guangxi Zhuang Autonomous Region of southern China , 2010, Clinical genetics.

[26]  M. Fleming,et al.  Identification of a Steap3 endosomal targeting motif essential for normal iron metabolism. , 2009, Blood.

[27]  J. Marine,et al.  Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised in TSAP6/Steap3-null mice , 2008, Cell Death and Differentiation.

[28]  M. Fleming,et al.  Structure of the membrane proximal oxidoreductase domain of human Steap3, the dominant ferrireductase of the erythroid transferrin cycle , 2008, Proceedings of the National Academy of Sciences.

[29]  H. Stefánsson,et al.  Genetics of gene expression and its effect on disease , 2008, Nature.

[30]  E. Birney,et al.  Pfam: the protein families database , 2013, Nucleic Acids Res..

[31]  M. Richardson.  Microcytic anemia. , 2007, Pediatrics in review.

[32]  M. Fleming,et al.  The Steap proteins are metalloreductases. , 2006, Blood.

[33]  M. Croft,et al.  Regulation of dendritic cell maturation and function by Bruton's tyrosine kinase via IL-10 and Stat3. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. J. Sharp,et al.  nm1054: a spontaneous, recessive, hypochromic, microcytic anemia mutation in the mouse. , 2005, Blood.

[35]  J. J. Sharp,et al.  Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells , 2005, Nature Genetics.

[36]  N. Müller,et al.  Drug-induced lung disease: high-resolution CT findings. , 2000, AJR. American journal of roentgenology.